Literature DB >> 21621174

Pityriasis rosea following influenza (H1N1) vaccination.

Jeng-Feng Chen1, Chien-Ping Chiang, Yu-Fei Chen, Wei-Ming Wang.   

Abstract

Pityriasis rosea is a distinct papulosquamous skin eruption that has been attributed to viral reactivation, certain drug exposures or rarely, vaccination. Herein, we reported a clinicopathlogically typical case of pityriasis rosea that developed after the H1N1 vaccination. With a global H1N1 vaccination program against the pandemic H1N1 influenza, patients should be apprised of the possibility of such rare but benign skin reaction to avoid unnecessary fear. Furthermore, a brief review of the current reported skin adverse events related to the novel H1N1 vaccination in Taiwan is presented here.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621174     DOI: 10.1016/j.jcma.2011.04.010

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  12 in total

1.  Interventions for pityriasis rosea.

Authors:  Jose Contreras-Ruiz; Sandra Peternel; Carlos Jiménez Gutiérrez; Ivana Culav-Koscak; Ludovic Reveiz; Maria de Lourdes Silbermann-Reynoso
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

2.  Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine.

Authors:  Olivia G Cohen; Ashley K Clark; Heather Milbar; Mordechai Tarlow
Journal:  Hum Vaccin Immunother       Date:  2021-08-26       Impact factor: 4.526

3.  Pemphigus vulgaris: A dermatological sequel of severe H1N1 infection.

Authors:  Preema Sinha; Manas Chatterjee; Biju Vasudevan
Journal:  Indian Dermatol Online J       Date:  2014-04

4.  An atypical case of pityriasis rosea gigantea after influenza vaccination.

Authors:  Dimitrios Papakostas; Panagiotis G Stavropoulos; Dafni Papafragkaki; Ekaterini Grigoraki; Georgia Avgerinou; Christina Antoniou
Journal:  Case Rep Dermatol       Date:  2014-04-18

5.  Recurrent Erythema Annulare Centrifugum due to Influenza Type A.

Authors:  Luca Ena; Vittorio Mazzarello; Marco Ferrari; Pasquale Ena
Journal:  Case Rep Dermatol       Date:  2021-02-18

6.  Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine.

Authors:  B M Cyrenne; F Al-Mohammedi; J G DeKoven; R Alhusayen
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-29       Impact factor: 9.228

Review 7.  Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review.

Authors:  Chii-Shyan Wang; Hsuan-Hsiang Chen; Shih-Hao Liu
Journal:  J Formos Med Assoc       Date:  2022-01-05       Impact factor: 3.871

8.  New Onset Guttate Psoriasis Following Pandemic H1N1 Influenza Vaccination.

Authors:  Moon Seub Shin; Soo Jin Kim; Seong Hyun Kim; Yee Gyoung Kwak; Hai-Jin Park
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

9.  Applicability of proposed diagnostic criteria of pityriasis rosea: results of a prospective case-control study in India.

Authors:  Vijay Zawar; Antonio Chuh
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

10.  Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines.

Authors:  J N Yu; C B Angeles; H G Lim; C Chavez; C Roxas-Rosete
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-17       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.